

Leonardo Pantoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1128748/publications.pdf>

Version: 2024-02-01

190
papers

22,272
citations

17429

63
h-index

9579

142
g-index

190
all docs

190
docs citations

190
times ranked

17264
citing authors

#	ARTICLE	IF	CITATIONS
1	The clinical profile of cerebral small vessel disease: Toward an evidence-based identification of cognitive markers. <i>Alzheimer's and Dementia</i> , 2023, 19, 244-260.	0.4	7
2	The Clock Drawing Test as a predictor of cognitive decline in non-demented stroke patients. <i>Journal of Neurology</i> , 2022, 269, 342-349.	1.8	6
3	Balance and visual reliance in post-COVID syndrome patients assessed with a robotic system: a multi-sensory integration deficit. <i>Neurological Sciences</i> , 2022, 43, 85-88.	0.9	8
4	Translations and cultural adaptations of the Montreal Cognitive Assessment: a systematic and qualitative review. <i>Neurological Sciences</i> , 2022, 43, 113-124.	0.9	9
5	Rapidly progressive dementia and intractable diarrhea: a teaching case report and a systematic review of cognitive impairment in Whipple's disease. <i>Neurological Sciences</i> , 2022, 43, 907-926.	0.9	7
6	Predictivity of the clock drawing test in the acute phase of cerebrovascular diseases on cognitive decline at a 6-month neuropsychological evaluation. <i>Neurological Sciences</i> , 2022, 43, 2073-2076.	0.9	2
7	Cognitive aspects of MELAS and CARASAL. <i>Cerebral Circulation - Cognition and Behavior</i> , 2022, 3, 100139.	0.4	0
8	A nationwide survey of Italian Centers for Cognitive Disorders and Dementia on the provision of care for international migrants. <i>European Journal of Neurology</i> , 2022, 29, 1892-1902.	1.7	5
9	Prediction of post-stroke cognitive impairment by Montreal Cognitive Assessment (MoCA) performances in acute stroke: comparison of three normative datasets. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 1855-1863.	1.4	6
10	Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study. <i>Stroke</i> , 2022, 53, 2620-2627.	1.0	28
11	Outcome of a Real-World Cohort of Patients Subjected to Endovascular Treatment for Acute Ischemic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106511.	0.7	1
12	Incipient chronic traumatic encephalopathy in active American football players: neuropsychological assessment and brain perfusion measures. <i>Neurological Sciences</i> , 2022, 43, 5383-5390.	0.9	2
13	The issue of dementia in migrants and ethnic minorities: the perspective of National Dementia Plans. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 2703-2708.	1.4	6
14	Epileptiform Activity During Transient Focal Neurologic Episodes in Cerebral Amyloid Angiopathy. <i>Neurology: Clinical Practice</i> , 2021, 11, e43-e45.	0.8	2
15	Cognitive evaluation in cerebral small vessel disease: towards an evidence-based identification of the reference standards. Part 1. A systematic review and qualitative data synthesis. <i>Journal of Neurology</i> , 2021, 268, 4563-4572.	1.8	14
16	What can longitudinal observational studies of physical activity teach us about prevention of dementia?. <i>Neurology</i> , 2021, 96, 10.1212/WNL.0000000000011376.	1.5	1
17	Longitudinal changes in MoCA performances in patients with mild cognitive impairment and small vessel disease. Results from the VMCI-Tuscany Study. <i>Cerebral Circulation - Cognition and Behavior</i> , 2021, 2, 100008.	0.4	1
18	The impact of lockdown during SARS-CoV-2 outbreak on behavioral and psychological symptoms of dementia. <i>Neurological Sciences</i> , 2021, 42, 825-833.	0.9	25

#	ARTICLE	IF	CITATIONS
19	Association of Bone Mineral Density to Cerebral Small Vessel Disease Burden. <i>Neurology</i> , 2021, 96, e1290-e1300.	1.5	13
20	Comparison of Oxford Cognitive Screen and Montreal Cognitive Assessment feasibility in the stroke unit setting. A pilot study. <i>Cerebral Circulation - Cognition and Behavior</i> , 2021, 2, 100021.	0.4	2
21	Cerebrovascular disease in patients with cognitive impairment: A white paper from the ESO dementia committee "A practical point of view with suggestions for the management of cerebrovascular diseases in memory clinics. <i>European Stroke Journal</i> , 2021, 6, 111-119.	2.7	9
22	Cognitive impairment in patients with cerebrovascular disease: A white paper from the links between stroke ESO Dementia Committee. <i>European Stroke Journal</i> , 2021, 6, 5-17.	2.7	37
23	Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i> , 2021, 52, 1450-1454.	1.0	7
24	Cognitive and behavioral manifestations in SARS-CoV-2 infection: not specific or distinctive features?. <i>Neurological Sciences</i> , 2021, 42, 2273-2281.	0.9	14
25	Efficacy and Safety of the Association of Nimodipine and Choline Alfoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial. <i>Drugs and Aging</i> , 2021, 38, 481-491.	1.3	6
26	ESO Guideline on covert cerebral small vessel disease. <i>European Stroke Journal</i> , 2021, 6, CXI-CLXII.	2.7	68
27	Location of infarcts and post-stroke cognitive impairment. <i>Lancet Neurology</i> , The, 2021, 20, 413-414.	4.9	7
28	ESO Guideline on covert cerebral small vessel disease. <i>European Stroke Journal</i> , 2021, 6, IV-IV.	2.7	14
29	Detection of subclinical atrial fibrillation after cryptogenic stroke using implantable cardiac monitors. <i>European Journal of Internal Medicine</i> , 2021, 92, 86-93.	1.0	15
30	CADASIL from Bench to Bedside: Disease Models and Novel Therapeutic Approaches. <i>Molecular Neurobiology</i> , 2021, 58, 2558-2573.	1.9	25
31	Stroke Care during the COVID-19 Pandemic: International Expert Panel Review. <i>Cerebrovascular Diseases</i> , 2021, 50, 245-261.	0.8	32
32	Cognitive disorders in migrants: retrospective analysis in a Center for Cognitive Disorders and Dementia in Milan. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 535-538.	1.4	7
33	Association of nimodipine and choline alfoscerate in the treatment of cognitive impairment in patients with cerebral small vessel disease: study protocol for a randomized placebo-controlled trial—the CONIVaD trial. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 449-457.	1.4	15
34	Ischemic stroke caused by giant cell arteritis associated with pulmonary adenocarcinoma. <i>Journal of Clinical Neuroscience</i> , 2020, 72, 485-486.	0.8	1
35	Brain atrophy in cerebral small vessel diseases: Extent, consequences, technical limitations and perspectives: The HARNES initiative. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 231-245.	2.4	49
36	Mild Cognitive Impairment in the Migrant Population Living in Europe: An Epidemiological Estimation of the Phenomenon. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 715-721.	1.2	6

#	ARTICLE	IF	CITATIONS
37	Respiratory dysfunction as first presentation of myasthenia gravis misdiagnosed as COVID-19. <i>Neurological Sciences</i> , 2020, 41, 3419-3421.	0.9	7
38	Neuropsychological screening in the acute phase of cerebrovascular diseases. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 377-384.	1.0	9
39	Dementia among migrants and ethnic minorities in Italy: rationale and study protocol of the ImmiDem project. <i>BMJ Open</i> , 2020, 10, e032765.	0.8	5
40	Stroke care in Italy at the time of the COVID-19 pandemic: a lesson to learn. <i>Journal of Neurology</i> , 2020, 268, 2307-2313.	1.8	10
41	Call to Action: SARS-CoV-2 and CerebrovAscular DisordErs (CASCADE). <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104938.	0.7	24
42	Understanding the Pathophysiology of Cerebral Amyloid Angiopathy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3435.	1.8	39
43	Diagnosing herpes simplex-1 encephalitis at the time of COVID-19 pandemic. <i>Neurological Sciences</i> , 2020, 41, 1361-1364.	0.9	15
44	Stroke care during the COVID-19 pandemic: experience from three large European countries. <i>European Journal of Neurology</i> , 2020, 27, 1794-1800.	1.7	128
45	Impact of the SARS-CoV-2 pandemic on stroke care: a warning message. <i>European Journal of Neurology</i> , 2020, 27, 1781-1782.	1.7	6
46	On being a neurologist in Italy at the time of the COVID-19 outbreak. <i>Neurology</i> , 2020, 94, 905-906.	1.5	71
47	Discovering the Italian phenotype of cerebral amyloid angiopathy (CAA): the SENECA project. <i>Neurological Sciences</i> , 2020, 41, 2193-2200.	0.9	3
48	Treatment-related transient splenial lesion of the Corpus Callosum in patients with neuropsychiatric disorders: a literature overview with a case report. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 315-325.	1.0	1
49	The role of the neuropsychologist in memory clinics. <i>Neurological Sciences</i> , 2020, 41, 1483-1488.	0.9	6
50	DTI-derived indexes of brain WM correlate with cognitive performance in vascular MCI and small-vessel disease. A TBSS study. <i>Brain Imaging and Behavior</i> , 2019, 13, 594-602.	1.1	16
51	Fractal dimension of cerebral white matter: A consistent feature for prediction of the cognitive performance in patients with small vessel disease and mild cognitive impairment. <i>NeuroImage: Clinical</i> , 2019, 24, 101990.	1.4	30
52	A semi-quantitative sport-specific assessment of recurrent traumatic brain injury: the TraQ questionnaire and its application in American football. <i>Neurological Sciences</i> , 2019, 40, 1909-1915.	0.9	16
53	Estimating dementia cases amongst migrants living in Europe. <i>European Journal of Neurology</i> , 2019, 26, 1191-1199.	1.7	27
54	Binaural stimulation in migraine: preliminary results from a 3-month evening treatment. <i>Neurological Sciences</i> , 2019, 40, 197-198.	0.9	4

#	ARTICLE	IF	CITATIONS
55	Harmonizing brain magnetic resonance imaging methods for vascular contributions to neurodegeneration. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 191-204.	1.2	65
56	Relevance of brain lesion location for cognition in vascular mild cognitive impairment. <i>NeuroImage: Clinical</i> , 2019, 22, 101789.	1.4	12
57	Cerebral small vessel disease and systemic arteriopathy in intracranial arterial dolichoectasia patients. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 150-157.	1.0	5
58	Qualitative Evaluation of the Immediate Copy of the Rey-Osterrieth Complex Figure: Comparison Between Vascular and Degenerative MCI Patients. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 14-23.	0.3	22
59	Transient global amnesia: an intriguing yet benign disturbance. <i>Arquivos De Neuro-Psiquiatria</i> , 2019, 77, 1-2.	0.3	3
60	Notch3 protein expression in skin fibroblasts from CADASIL patients. <i>Journal of the Neurological Sciences</i> , 2018, 390, 121-128.	0.3	1
61	Application of the DSM-5 Criteria for Major Neurocognitive Disorder to Vascular MCI Patients. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2018, 8, 104-116.	0.6	13
62	Vascular cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18003.	18.1	358
63	Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. <i>Alzheimer's and Dementia</i> , 2018, 14, 280-292.	0.4	246
64	Mixed-location cerebral hemorrhage/microbleeds. <i>Neurology</i> , 2018, 90, e119-e126.	1.5	128
65	P2ŕ: THE COMBINED EFFECT OF COGNITIVE IMPAIRMENT AND PHYSICAL FRAILITY ON DEMENTIA INCIDENCE: SYSTEMATIC REVIEW AND METAâANALYSIS. <i>Alzheimer's and Dementia</i> , 2018, 14, P816.	0.4	0
66	Functional magnetic resonance imaging with encoding task in patients with mild cognitive impairment and different severity of leukoaraiosis. <i>Psychiatry Research - Neuroimaging</i> , 2018, 282, 126-131.	0.9	5
67	May migraine attack response to triptans be a predictor of the efficacy of Onabotulinum toxin-A prophylaxis?. <i>Neurological Sciences</i> , 2018, 39, 153-154.	0.9	8
68	Estimating dementia cases in the immigrant population living in Italy. <i>Neurological Sciences</i> , 2018, 39, 1775-1778.	0.9	6
69	Personality traits in migraineurs: a case-control study by personality inventory for DSM-5 (PID-5). <i>Neurological Sciences</i> , 2018, 39, 129-130.	0.9	5
70	Location, number and factors associated with cerebral microbleeds in an Italian-British cohort of CADASIL patients. <i>PLoS ONE</i> , 2018, 13, e0190878.	1.1	33
71	The brain effect of the migraine attack: an ASL MRI study of the cerebral perfusion during a migraine attack. <i>Neurological Sciences</i> , 2018, 39, 73-74.	0.9	8
72	Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects. <i>BMC Medicine</i> , 2017, 15, 41.	2.3	212

#	ARTICLE	IF	CITATIONS
73	Visuospatial Functioning in Cerebral Amyloid Angiopathy: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1223-1227.	1.2	12
74	Distribution of lacunes in cerebral amyloid angiopathy and hypertensive small vessel disease. <i>Neurology</i> , 2017, 88, 2162-2168.	1.5	112
75	Have Stroke Neurologists Entered the Arena of Stroke-Related Cognitive Dysfunctions?. <i>Stroke</i> , 2017, 48, 1441-1442.	1.0	20
76	Pregnancy in CADASIL. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 668-671.	1.0	6
77	The Vascular Impairment of Cognition Classification Consensus Study. <i>Alzheimer's and Dementia</i> , 2017, 13, 624-633.	0.4	143
78	Resting state fMRI regional homogeneity correlates with cognition measures in subcortical vascular cognitive impairment. <i>Journal of the Neurological Sciences</i> , 2017, 373, 1-6.	0.3	36
79	Effect of Attention Training in Mild Cognitive Impairment Patients with Subcortical Vascular Changes: The RehAtt Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 615-624.	1.2	21
80	Leukoaraiosis as an outcome predictor in the acute and subacute phases of stroke. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 963-975.	1.4	21
81	Total small vessel disease burden and brain network efficiency in cerebral amyloid angiopathy. <i>Journal of the Neurological Sciences</i> , 2017, 382, 10-12.	0.3	16
82	Antipsychotics and Cerebrovascular Accidents: Taking or Not the Risk?. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 651-652.	1.2	1
83	Heterozygous mutations of <i>HTRA1</i> gene in patients with familial cerebral small vessel disease. <i>CNS Neuroscience and Therapeutics</i> , 2017, 23, 759-765.	1.9	46
84	Thrombolysis in dementia patients with acute stroke: is it justified?. <i>Neurological Sciences</i> , 2017, 38, 27-31.	0.9	23
85	Diffusion Tensor Imaging to Map Brain Microstructural Changes in CADASIL. <i>Journal of Neuroimaging</i> , 2017, 27, 85-91.	1.0	22
86	Circulating Biomarkers in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Patients. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 823-833.	0.7	12
87	White matter microstructural damage and depressive symptoms in patients with mild cognitive impairment and cerebral small vessel disease: the VMCI-Tuscany Study. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 611-618.	1.3	15
88	The rehabilitation of attention in patients with mild cognitive impairment and brain subcortical vascular changes using the Attention Process Training-II. The RehAtt Study: rationale, design and methodology. <i>Neurological Sciences</i> , 2016, 37, 1653-1662.	0.9	11
89	Reproducibility and variability of quantitative magnetic resonance imaging markers in cerebral small vessel disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 1319-1337.	2.4	80
90	White Matter Microstructural Damage on Diffusion Tensor Imaging in Cerebral Small Vessel Disease. <i>Stroke</i> , 2016, 47, 1679-1684.	1.0	80

#	ARTICLE	IF	CITATIONS
91	METACOHORTS for the study of vascular disease and its contribution to cognitive decline and neurodegeneration: An initiative of the Joint Programme for Neurodegenerative Disease Research. <i>Alzheimer's and Dementia</i> , 2016, 12, 1235-1249.	0.4	82
92	Leukoaraiosis, Cerebral Hemorrhage, and Outcome After Intravenous Thrombolysis for Acute Ischemic Stroke. <i>Stroke</i> , 2016, 47, 2364-2372.	1.0	75
93	Cerebral microbleeds in patients with mild cognitive impairment and small vessel disease: The Vascular Mild Cognitive Impairment (VMCI)-Tuscany study. <i>Journal of the Neurological Sciences</i> , 2016, 368, 195-202.	0.3	27
94	The Relevance of Assessing Cognitive Performances in Patients With Cerebrovascular Diseases. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 458-459.	1.2	1
95	Prediction of Impaired Performance in Trail Making Test in MCI Patients With Small Vessel Disease Using DTI Data. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2016, 20, 1026-1033.	3.9	27
96	Operationalizing mild cognitive impairment criteria in small vessel disease: the VMCI-Tuscany Study. , 2016, 12, 407-418.		34
97	Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease: A review. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 72-94.	2.4	197
98	Impact of cerebral white matter changes on functionality in older adults: An overview of the LADIS Study results and future directions. <i>Geriatrics and Gerontology International</i> , 2015, 15, 10-16.	0.7	56
99	Clinical, familial, and neuroimaging features of CADASIL-like patients. <i>Acta Neurologica Scandinavica</i> , 2015, 131, 30-36.	1.0	13
100	Is type 2 diabetes related to leukoaraiosis? an updated review. <i>Acta Neurologica Scandinavica</i> , 2015, 132, 147-155.	1.0	48
101	Atrial Fibrillation and Cognition. <i>Stroke</i> , 2015, 46, 3316-3321.	1.0	56
102	Moyamoya in a patient with Sneddon's syndrome. <i>Clinical Neurology and Neurosurgery</i> , 2015, 129, 34-36.	0.6	10
103	White Matter Microstructural Damage in Small Vessel Disease Is Associated With Montreal Cognitive Assessment But Not With Mini Mental State Examination Performances. <i>Stroke</i> , 2015, 46, 262-264.	1.0	47
104	Physical activity in the elderly is associated with improved executive function and processing speed: the LADIS Study. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 744-750.	1.3	51
105	The burden of microstructural damage modulates cortical activation in elderly subjects with MCI and leukoaraiosis. A DTI and fMRI study. <i>Human Brain Mapping</i> , 2014, 35, 819-830.	1.9	48
106	Thrombolysis in Acute Stroke Patients with Cerebral Small Vessel Disease. <i>Cerebrovascular Diseases</i> , 2014, 37, 5-13.	0.8	84
107	Use of Montreal Cognitive Assessment in Patients With Stroke. <i>Stroke</i> , 2014, 45, 3135-3140.	1.0	107
108	Effects of Sapropterin on Endothelium-Dependent Vasodilation in Patients With CADASIL. <i>Stroke</i> , 2014, 45, 2959-2966.	1.0	16

#	ARTICLE	IF	CITATIONS
109	Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study. Journal of Neurology, 2014, 261, 1160-1169.	1.8	16
110	Influence of vascular risk factors and neuropsychological profile on functional performances in CADASIL: results from the Microvascular LEukoencephalopathy Study (MILES). European Journal of Neurology, 2014, 21, 65-71.	1.7	21
111	Development and Psychometric Properties of a Neuropsychological Battery for Mild Cognitive Impairment with Small Vessel Disease: The VMCI-Tuscany Study. Journal of Alzheimer's Disease, 2014, 43, 1313-1323.	1.2	29
112	The Florence VAS-COG Clinic: A Model for the Care of Patients with Cognitive and Behavioral Disturbances Consequent to Cerebrovascular Diseases. Journal of Alzheimer's Disease, 2014, 42, S453-S461.	1.2	10
113	Sporadic small vessel disease: pathogenic aspects. , 2014, , 52-63.		8
114	Deterioration of Gait and Balance over Time: The Effects of Age-Related White Matter Change - The LADIS Study. Cerebrovascular Diseases, 2013, 35, 544-553.	0.8	65
115	Predictive value of MoCA in the acute phase of stroke on the diagnosis of mid-term cognitive impairment. Journal of Neurology, 2013, 260, 2220-2227.	1.8	77
116	Factors predicting the Montreal cognitive assessment (MoCA) applicability and performances in a stroke unit. Journal of Neurology, 2013, 260, 1518-1526.	1.8	46
117	Cerebral white matter changes are associated with abnormalities on neurological examination in non-disabled elderly: the LADIS study. Journal of Neurology, 2013, 260, 1014-1021.	1.8	34
118	Cerebral hemorrhages in CADASIL: Report of four cases and a brief review. Journal of the Neurological Sciences, 2013, 330, 45-51.	0.3	43
119	Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurology, The, 2013, 12, 822-838.	4.9	3,919
120	Diffusion changes predict cognitive and functional outcome: The <sc>LADIS</sc> study. Annals of Neurology, 2013, 73, 576-583.	2.8	66
121	Facial Affect Recognition in CADASIL Patients. Archives of Clinical Neuropsychology, 2013, 28, 65-71.	0.3	5
122	Impaired vasoreactivity in mildly disabled CADASIL patients. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 268-274.	0.9	18
123	White Matter Lesion Progression in LADIS. Stroke, 2012, 43, 2643-2647.	1.0	88
124	Physical Activity Prevents Progression for Cognitive Impairment and Vascular Dementia. Stroke, 2012, 43, 3331-3335.	1.0	98
125	The Cerebral Autosomal-Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Scale. Stroke, 2012, 43, 2871-2876.	1.0	68
126	The VAS-COG clinic: an out-patient service for patients with cognitive and behavioral consequences of cerebrovascular diseases. Neurological Sciences, 2012, 33, 1277-1283.	0.9	13

#	ARTICLE	IF	CITATIONS
127	Risk and Determinants of Dementia in Patients with Mild Cognitive Impairment and Brain Subcortical Vascular Changes: A Study of Clinical, Neuroimaging, and Biological Markersâ€”The VMCI-Tuscany Study: Rationale, Design, and Methodology. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-7.	1.1	26
128	Brain atrophy accelerates cognitive decline in cerebral small vessel disease. <i>Neurology</i> , 2012, 78, 1785-1792.	1.5	125
129	Post-Stroke Dementia and Cognitive Impairment. <i>Frontiers of Neurology and Neuroscience</i> , 2012, 30, 65-69.	3.0	55
130	Acetazolamide for the prophylaxis of migraine in CADASIL: a preliminary experience. <i>Journal of Headache and Pain</i> , 2012, 13, 299-302.	2.5	26
131	Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: A 3-year follow-up of the LADIS study cohort. <i>Journal of the Neurological Sciences</i> , 2011, 307, 100-105.	0.3	57
132	2001â€”2011: A Decade of the LADIS (Leukoaraiosis And DISability) Study: What Have We Learned about White Matter Changes and Small-Vessel Disease?. <i>Cerebrovascular Diseases</i> , 2011, 32, 577-588.	0.8	258
133	Advances in Vascular Cognitive Impairment 2010. <i>Stroke</i> , 2011, 42, 291-293.	1.0	24
134	The use of CT in dementia. <i>International Psychogeriatrics</i> , 2011, 23, S6-S12.	0.6	31
135	Self-Perceived Memory Complaints Predict Progression to Alzheimer Disease. The LADIS Study. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 491-498.	1.2	21
136	Incident lacunes influence cognitive decline. <i>Neurology</i> , 2011, 76, 1872-1878.	1.5	183
137	Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. <i>Lancet Neurology</i> , The, 2010, 9, 689-701.	4.9	2,586
138	Diffusion-Weighted Imaging and Cognition in the Leukoaraiosis and Disability in the Elderly Study. <i>Stroke</i> , 2010, 41, e402-8.	1.0	82
139	Comparison of clinical, familial, and MRI features of CADASIL and <i>NOTCH3</i> -negative patients. <i>Neurology</i> , 2010, 74, 57-63.	1.5	83
140	Bone Marrow-Derived Progenitor Cells in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. <i>Stroke</i> , 2010, 41, 218-223.	1.0	28
141	Relationship between baseline white-matter changes and development of late-life depressive symptoms: 3-year results from the LADIS study. <i>Psychological Medicine</i> , 2010, 40, 603-610.	2.7	119
142	White matter changes and diabetes predict cognitive decline in the elderly. <i>Neurology</i> , 2010, 75, 160-167.	1.5	171
143	Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 478-483.	0.9	102
144	Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. <i>BMJ: British Medical Journal</i> , 2009, 339, b2477-b2477.	2.4	348

#	ARTICLE	IF	CITATIONS
145	Deep frontal and periventricular age related white matter changes but not basal ganglia and infratentorial hyperintensities are associated with falls: cross sectional results from the LADIS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 608-613.	0.9	127
146	Cognitive Decline and Dementia Related to Cerebrovascular Diseases: Some Evidence and Concepts. <i>Cerebrovascular Diseases</i> , 2009, 27, 191-196.	0.8	74
147	MRI-Defined Subcortical Ischemic Vascular Disease: Baseline Clinical and Neuropsychological Findings. <i>Cerebrovascular Diseases</i> , 2009, 27, 336-344.	0.8	78
148	Longitudinal Cognitive Decline in Subcortical Ischemic Vascular Disease – The LADIS Study. <i>Cerebrovascular Diseases</i> , 2009, 27, 384-391.	0.8	167
149	Psychiatric disturbances in CADASIL: a brief review. <i>Acta Neurologica Scandinavica</i> , 2008, 118, 291-295.	1.0	51
150	Urinary Complaints in Nondisabled Elderly People with Age-Related White Matter Changes: The Leukoaraiosis And Disability (LADIS) Study. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 1638-1643.	1.3	81
151	A pathogenic mutation on exon 21 of the NOTCH3 gene causing CADASIL in an octogenarian paucisymptomatic patient. <i>Journal of the Neurological Sciences</i> , 2008, 267, 170-173.	0.3	32
152	Self-perceived memory impairment and cognitive performance in an elderly independent population with age-related white matter changes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 869-873.	0.9	42
153	Association of gait and balance disorders with age-related white matter changes. <i>Neurology</i> , 2008, 70, 935-942.	1.5	374
154	Progression of White Matter Hyperintensities and Incidence of New Lacunes Over a 3-Year Period. <i>Stroke</i> , 2008, 39, 1414-1420.	1.0	348
155	Leukoaraiosis: From an Ancient Term to an Actual Marker of Poor Prognosis. <i>Stroke</i> , 2008, 39, 1401-1403.	1.0	61
156	On the Etiology of Incident Brain Lacunes. <i>Stroke</i> , 2008, 39, 3083-3085.	1.0	76
157	Risk of Rapid Global Functional Decline in Elderly Patients With Severe Cerebral Age-Related White Matter Changes. <i>Archives of Internal Medicine</i> , 2007, 167, 81.	4.3	187
158	Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1325-1330.	0.9	136
159	The relation between white-matter lesions and cognition. <i>Current Opinion in Neurology</i> , 2007, 20, 390-397.	1.8	131
160	Clinical significance of corpus callosum atrophy in a mixed elderly population. <i>Neurobiology of Aging</i> , 2007, 28, 955-963.	1.5	67
161	White matter changes and late-life depressive symptoms. <i>British Journal of Psychiatry</i> , 2007, 191, 212-217.	1.7	141
162	The effect of white matter lesions on cognition in the elderly – “small but detectable”. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 620-627.	2.7	104

#	ARTICLE	IF	CITATIONS
163	White Matter Hyperintensities Rather Than Lacunar Infarcts Are Associated With Depressive Symptoms in Older People: The LADIS Study. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 834-841.	0.6	141
164	Leukoaraiosis Predicts Hidden Global Functioning Impairment in Nondisabled Older People: The LADIS (Leukoaraiosis and Disability in the Elderly) Study. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1095-1101.	1.3	83
165	Relationship between periventricular and deep white matter lesions and depressive symptoms in older people. The LADIS Study. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 983-989.	1.3	94
166	Development of a Neuropsychological Battery for the Leukoaraiosis and Disability in the Elderly Study (LADIS): Experience and Baseline Data. <i>Neuroepidemiology</i> , 2006, 27, 101-116.	1.1	67
167	Corpus callosum atrophy is associated with mental slowing and executive deficits in subjects with age-related white matter hyperintensities: the LADIS Study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 491-496.	0.9	90
168	Clinical features, risk factors, and prognosis in transient global amnesia: a follow-up study. <i>European Journal of Neurology</i> , 2005, 12, 350-356.	1.7	109
169	Postpartum psychiatric disturbances as an unrecognized onset of CADASIL. <i>Acta Psychiatrica Scandinavica</i> , 2005, 112, 241-241.	2.2	14
170	White matter hyperintensities and depression—preliminary results from the LADIS study. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 674-679.	1.3	56
171	Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1497-1500.	0.9	96
172	Efficacy and Safety of Nimodipine in Subcortical Vascular Dementia. <i>Stroke</i> , 2005, 36, 619-624.	1.0	100
173	Small Vessel Disease and General Cognitive Function in Nondisabled Elderly. <i>Stroke</i> , 2005, 36, 2116-2120.	1.0	311
174	Impact of Age-Related Cerebral White Matter Changes on the Transition to Disability—The LADIS Study: Rationale, Design and Methodology. <i>Neuroepidemiology</i> , 2005, 24, 51-62.	1.1	387
175	White matter lesion progression. <i>Neurology</i> , 2004, 63, 139-144.	1.5	163
176	Treatment of vascular dementia: evidence from trials with non-cholinergic drugs. <i>Journal of the Neurological Sciences</i> , 2004, 226, 67-70.	0.3	29
177	Vascular cognitive impairment. <i>Lancet Neurology</i> , The, 2003, 2, 89-98.	4.9	1,130
178	Visual Rating Scales for Age-Related White Matter Changes (Leukoaraiosis). <i>Stroke</i> , 2002, 33, 2827-2833.	1.0	101
179	A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT. <i>Stroke</i> , 2001, 32, 1318-1322.	1.0	1,506
180	Transient global amnesia: a review emphasizing pathogenic aspects. <i>Acta Neurologica Scandinavica</i> , 2000, 102, 275-283.	1.0	101

#	ARTICLE	IF	CITATIONS
181	Limitations of Clinical Criteria for the Diagnosis of Vascular Dementia in Clinical Trials: Is a Focus on Subcortical Vascular Dementia a Solution?. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 262-272.	1.8	100
182	Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. <i>Journal of the Neurological Sciences</i> , 2000, 175, 124-134.	0.3	89
183	The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. <i>Journal of the Neurological Sciences</i> , 2000, 175, 116-123.	0.3	61
184	Research criteria for subcortical vascular dementia in clinical trials. , 2000, 59, 23-30.		414
185	Emotional Arousal and Phobia in Transient Global Amnesia. <i>Archives of Neurology</i> , 1997, 54, 866-873.	4.9	85
186	Pathogenesis of Leukoaraiosis. <i>Stroke</i> , 1997, 28, 652-659.	1.0	1,050
187	A Preliminary Open Trial with Nimodipine in Patients with Cognitive Impairment and Leukoaraiosis. <i>Clinical Neuropharmacology</i> , 1996, 19, 497-506.	0.2	38
188	Cerebral White Matter Is Highly Vulnerable to Ischemia. <i>Stroke</i> , 1996, 27, 1641-1647.	1.0	535
189	The Significance of Cerebral White Matter Abnormalities 100 Years After Binswanger's Report. <i>Stroke</i> , 1995, 26, 1293-1301.	1.0	427
190	Pathology of cerebral small vessel disease. , 0, , 4-15.		9